Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Retained Earnings: 2023-2024

Historic Retained Earnings for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$117.4 million.

  • Contineum Therapeutics' Retained Earnings fell 57.75% to -$162.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.2 million, marking a year-over-year decrease of 57.75%. This contributed to the annual value of -$117.4 million for FY2024, which is 56.24% down from last year.
  • According to the latest figures from FY2024, Contineum Therapeutics' Retained Earnings is -$117.4 million, which was down 56.24% from -$75.1 million recorded in FY2023.
  • Contineum Therapeutics' 5-year Retained Earnings high stood at -$75.1 million for FY2023, and its period low was -$117.4 million during FY2024.
  • For the 2-year period, Contineum Therapeutics' Retained Earnings averaged around -$96.3 million, with its median value being -$96.3 million (2023).
  • Data for Contineum Therapeutics' Retained Earnings shows a maximum YoY plummeted of 56.24% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Retained Earnings stood at -$75.1 million in 2023, then crashed by 56.24% to -$117.4 million in 2024.